ZA200704130B - Protassium salt of an HIV integrase inhibitor - Google Patents
Protassium salt of an HIV integrase inhibitorInfo
- Publication number
- ZA200704130B ZA200704130B ZA200704130A ZA200704130A ZA200704130B ZA 200704130 B ZA200704130 B ZA 200704130B ZA 200704130 A ZA200704130 A ZA 200704130A ZA 200704130 A ZA200704130 A ZA 200704130A ZA 200704130 B ZA200704130 B ZA 200704130B
- Authority
- ZA
- South Africa
- Prior art keywords
- protassium
- salt
- hiv integrase
- integrase inhibitor
- inhibitor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
- C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
- C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/557—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms, e.g. orotic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D313/00—Heterocyclic compounds containing rings of more than six members having one oxygen atom as the only ring hetero atom
- C07D313/02—Seven-membered rings
- C07D313/06—Seven-membered rings condensed with carbocyclic rings or ring systems
- C07D313/10—Seven-membered rings condensed with carbocyclic rings or ring systems condensed with two six-membered rings
- C07D313/12—[b,e]-condensed
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US63313204P | 2004-12-03 | 2004-12-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200704130B true ZA200704130B (en) | 2008-08-27 |
Family
ID=36171569
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200704130A ZA200704130B (en) | 2004-12-03 | 2007-05-22 | Protassium salt of an HIV integrase inhibitor |
Country Status (35)
| Country | Link |
|---|---|
| US (2) | US7754731B2 (OSRAM) |
| EP (2) | EP1819683B1 (OSRAM) |
| JP (1) | JP4705956B2 (OSRAM) |
| KR (2) | KR101350420B1 (OSRAM) |
| CN (1) | CN101068793B (OSRAM) |
| AR (2) | AR052034A1 (OSRAM) |
| AT (2) | ATE534645T1 (OSRAM) |
| AU (1) | AU2005311671B8 (OSRAM) |
| BR (1) | BRPI0518760A8 (OSRAM) |
| CA (1) | CA2588398C (OSRAM) |
| CR (1) | CR9146A (OSRAM) |
| CY (1) | CY1112859T1 (OSRAM) |
| DK (1) | DK1819700T3 (OSRAM) |
| EA (1) | EA012418B1 (OSRAM) |
| ES (2) | ES2375788T3 (OSRAM) |
| GE (1) | GEP20105086B (OSRAM) |
| HR (1) | HRP20120066T1 (OSRAM) |
| IL (1) | IL183614A (OSRAM) |
| MA (1) | MA29120B1 (OSRAM) |
| ME (1) | ME01985B (OSRAM) |
| MX (1) | MX2007006639A (OSRAM) |
| MY (1) | MY144320A (OSRAM) |
| NI (1) | NI200700138A (OSRAM) |
| NO (1) | NO338784B1 (OSRAM) |
| NZ (1) | NZ555376A (OSRAM) |
| PE (1) | PE20061148A1 (OSRAM) |
| PL (1) | PL1819700T3 (OSRAM) |
| PT (1) | PT1819700E (OSRAM) |
| RS (1) | RS52197B (OSRAM) |
| SI (1) | SI1819700T1 (OSRAM) |
| TN (1) | TNSN07215A1 (OSRAM) |
| TW (1) | TWI344463B (OSRAM) |
| UA (1) | UA87884C2 (OSRAM) |
| WO (2) | WO2006060712A2 (OSRAM) |
| ZA (1) | ZA200704130B (OSRAM) |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1725528B1 (en) | 2004-03-11 | 2013-05-29 | 4Sc Ag | Sulphonylpyrroles as hdac inhibitors |
| TR201907729T4 (tr) * | 2004-12-03 | 2019-06-21 | Merck Sharp & Dohme | Bir anti-çekirdekleştirici ajan içeren farmasötik bileşim. |
| US8852632B2 (en) * | 2004-12-03 | 2014-10-07 | Merck Sharp & Dohme Corp. | Pharmaceutical formulation containing a release rate controlling composition |
| US20070259894A1 (en) * | 2004-12-03 | 2007-11-08 | Kelem Kassahun | Use of Atazanavir for Improving the Pharmacokinetics of Drugs Metabolized by Ugt1a1 |
| WO2007106768A2 (en) * | 2006-03-14 | 2007-09-20 | Merck & Co., Inc. | Processes and apparatuses for the production of crystalline organic microparticle compositions by micro-milling and crystallization on micro-seed and their use |
| AU2007275805A1 (en) | 2006-07-19 | 2008-01-24 | University Of Georgia Research Foundation, Inc. | Pyridinone diketo acids: Inhibitors of HIV replication in combination therapy |
| US7687509B2 (en) * | 2007-07-09 | 2010-03-30 | Concert Pharmaceuticals Inc. | Pyrimidinecarboxamide derivatives |
| CN103254138A (zh) * | 2008-01-08 | 2013-08-21 | 默沙东公司 | 用于制备n-取代的羟基嘧啶酮羧酰胺类化合物的方法 |
| US8742105B2 (en) | 2009-06-02 | 2014-06-03 | Hetero Research Foundation | Polymorphs of raltegravir potassium |
| WO2011024192A2 (en) | 2009-07-27 | 2011-03-03 | Matrix Laboratories Ltd | Novel polymorphs of raltegravir |
| HUE057248T2 (hu) * | 2009-10-26 | 2022-04-28 | Merck Sharp & Dohme | Integráz inhibitort tartalmazó szilárd gyógyszerészeti kompozíciók |
| DE102009056636A1 (de) | 2009-12-02 | 2011-06-09 | Ratiopharm Gmbh | Raltegravir-Polymorphe |
| EA201270651A1 (ru) * | 2009-12-07 | 2013-01-30 | Юниверсити Оф Джорджия Рисерч Фаундейшн, Инк. | Карбоксамиды пиридинон гидроксициклопентила: ингибиторы вич интегразы и области терапевтического применения |
| ES2362598B1 (es) * | 2009-12-17 | 2012-06-13 | Consejo Superior De Investigaciones Científicas (Csic) | Uso del raltegravir y derivados para la elaboración de medicamentos destinados al tratamiento de infecciones por herpesvirus. |
| CA2794952C (en) * | 2010-04-01 | 2018-05-15 | Critical Outcome Technologies Inc. | Compounds and method for treatment of hiv |
| EP2545048B1 (en) * | 2010-04-01 | 2014-10-08 | Teva Pharmaceutical Industries Ltd. | Raltegravir salts and crystalline forms thereof |
| EP2575465A4 (en) * | 2010-05-25 | 2013-11-20 | Hetero Research Foundation | Raltegravir SALTS |
| US9107922B2 (en) | 2010-07-16 | 2015-08-18 | Concert Pharmaceuticals, Inc. | Pyrimidinecarboxamide derivatives |
| CN101914067B (zh) * | 2010-08-26 | 2012-07-11 | 陈岱岭 | N-甲基嘧啶酮的合成方法 |
| JO3209B1 (ar) * | 2010-11-05 | 2018-03-08 | H Lundbeck As | طريقة لتصنيع نالتريكسون |
| WO2012103105A1 (en) | 2011-01-24 | 2012-08-02 | Assia Chemical Industries Ltd. | Processes for preparing raltegravir and intermediates in the processes |
| WO2012106534A2 (en) * | 2011-02-02 | 2012-08-09 | The Regents Of The University Of California | Hiv integrase inhibitors |
| AU2012241050B2 (en) | 2011-04-06 | 2016-05-19 | Lupin Limited | Novel salts of raltegravir |
| EP2699094A4 (en) * | 2011-04-22 | 2014-12-17 | Merck Sharp & Dohme | TASTE-MASKED FORMULATIONS BY RALTEGRAVIR |
| US9968607B2 (en) | 2011-04-25 | 2018-05-15 | Hetero Research Foundation | Pharmaceutical compositions of raltegravir, methods of preparation and methods of use therof |
| EP2522665A1 (en) * | 2011-05-03 | 2012-11-14 | Sandoz Ag | Crystalline sodium salt of an HIV integrase inhibitor |
| EP2529741B1 (en) | 2011-06-01 | 2014-02-12 | Ratiopharm GmbH | Composition and Tablet Comprising Raltegravir |
| WO2013037731A1 (de) | 2011-09-16 | 2013-03-21 | Hexal Ag | Neue polymorphe form von raltegravir-kalium |
| CN103130787B (zh) * | 2011-11-24 | 2015-06-10 | 南开大学 | 嘧啶酮酰胺类化合物及其制备方法、抗hiv活性和抗tmv活性 |
| CN103130788B (zh) * | 2011-11-24 | 2015-09-02 | 南开大学 | 嘧啶酰胺类化合物及其制备方法、抗hiv活性和抗tmv活性 |
| WO2013098854A2 (en) * | 2011-12-26 | 2013-07-04 | Emcure Pharmaceuticals Limited | Synthesis of raltegravir |
| JP2015504913A (ja) | 2012-01-25 | 2015-02-16 | ルピン・リミテッドＬｕｐｉｎ Ｌｉｍｉｔｅｄ | 安定な非晶質のラルテグラビルカリウムプレミックス、及び、その調製方法 |
| WO2014064711A2 (en) * | 2012-10-22 | 2014-05-01 | Hetero Research Foundation | Methods of administering raltegravir and raltegravir compositions |
| EP2818470A1 (en) | 2013-06-27 | 2014-12-31 | Basf Se | Cocrystals of raltegravir potassium |
| EP3022209B1 (en) * | 2013-07-17 | 2018-03-07 | ratiopharm GmbH | Dolutegravir potassium salt |
| EP3102565B1 (en) | 2014-02-03 | 2019-01-02 | Mylan Laboratories Ltd. | Processes for the preparation of intermediates of raltegravir |
| US10391178B2 (en) | 2014-03-21 | 2019-08-27 | Mylan Laboratories Limited | Premix of crystalline raltegravir potassium salt and a process for the preparation thereof |
| US10257840B2 (en) | 2014-10-22 | 2019-04-09 | Telefonaktiebolaget Lm Ericsson (Publ) | Operation of wireless local area network in the presence of periodic interference |
| US10259778B2 (en) | 2014-11-10 | 2019-04-16 | Aurobindo Pharma Ltd | Process for the preparation of raltegravir |
| EP3472134B1 (en) | 2016-06-21 | 2021-10-20 | Pharmathen S.A. | Process for preparing compounds useful as intermediates for the preparation of raltegravir |
| US10752618B2 (en) | 2016-09-15 | 2020-08-25 | Lupin Limited | Process for the preparation of pure and stable crystalline Raltegravir potassium form 3 |
| CN108610338A (zh) * | 2016-12-12 | 2018-10-02 | 天津国际生物医药联合研究院 | 一种嘧啶酮酰胺类化合物的制备方法 |
| WO2019096773A1 (en) | 2017-11-14 | 2019-05-23 | Cambrex Profarmaco Milano S.R.L. | Process for the preparation of raltegravir |
| WO2019236395A1 (en) * | 2018-06-06 | 2019-12-12 | Merck Sharp & Dohme Corp. | Formulations of raltegravir |
| GB201907305D0 (en) * | 2019-05-23 | 2019-07-10 | Douglas Pharmaceuticals Ltd | Treatment of conditions |
| EP4093380A1 (en) | 2020-01-23 | 2022-11-30 | Lupin Limited | Pharmaceutical compositions of raltegravir |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH624391A5 (OSRAM) * | 1976-12-14 | 1981-07-31 | Ciba Geigy Ag | |
| US5717097A (en) | 1991-11-08 | 1998-02-10 | Merck & Co., Inc. | HIV protease inhibitors useful for the treatment of AIDS |
| US5413999A (en) | 1991-11-08 | 1995-05-09 | Merck & Co., Inc. | HIV protease inhibitors useful for the treatment of AIDS |
| IL121789A (en) * | 1996-10-03 | 2001-06-14 | Rohm & Haas | A medicinal product for inhibiting mammalian cell tumors |
| RU2225860C2 (ru) | 1998-12-25 | 2004-03-20 | Шионоги & Ко., Лтд. | Ароматические гетероциклические соединения, обладающие активностью в отношении вич-интегразы |
| IT1318424B1 (it) | 2000-03-24 | 2003-08-25 | Unihart Corp | Composti con attivita' anti-hiv. |
| IL155089A0 (en) | 2000-10-12 | 2003-10-31 | Merck & Co Inc | Aza and polyaza-naphthalenyl carboxamides useful as hiv integrase inhibitors |
| GB0028483D0 (en) | 2000-11-22 | 2001-01-10 | Hoffmann La Roche | Hydroxyethylamine HIV protease inhibitors |
| DK1441735T3 (da) | 2001-10-26 | 2006-06-12 | Angeletti P Ist Richerche Bio | N-substituerede hydroxypyrimidinon-carboxamid-inhibitorer af HIV-integrase |
| US7354932B2 (en) | 2001-12-21 | 2008-04-08 | Anormed, Inc. | Chemokine receptor binding heterocyclic compounds with enhanced efficacy |
| CN1596255A (zh) | 2001-12-21 | 2005-03-16 | 阿诺麦德股份有限公司 | 具有强效的与趋化因子受体结合的杂环化合物 |
| SI1564210T1 (sl) | 2002-11-20 | 2010-01-29 | Japan Tobacco Inc | 4-oksokinolinske spojine in njihova uporaba kot inhibitorji HIV integraze |
| KR20050087865A (ko) | 2002-12-27 | 2005-08-31 | 이스티투토 디 리세르쉐 디 비올로지아 몰레콜라레 피. 안젤레티에스.피.에이. | ＨＩＶ 인테그라제 억제제로서 유용한테트라하이드로-4Ｈ-피리도[1,2-ａ]피리미딘 및 관련화합물 |
| TW200423930A (en) | 2003-02-18 | 2004-11-16 | Hoffmann La Roche | Non-nucleoside reverse transcriptase inhibitors |
| US8852632B2 (en) * | 2004-12-03 | 2014-10-07 | Merck Sharp & Dohme Corp. | Pharmaceutical formulation containing a release rate controlling composition |
| TR201907729T4 (tr) | 2004-12-03 | 2019-06-21 | Merck Sharp & Dohme | Bir anti-çekirdekleştirici ajan içeren farmasötik bileşim. |
| US20070259894A1 (en) | 2004-12-03 | 2007-11-08 | Kelem Kassahun | Use of Atazanavir for Improving the Pharmacokinetics of Drugs Metabolized by Ugt1a1 |
-
2005
- 2005-02-12 UA UAA200707372A patent/UA87884C2/uk unknown
- 2005-11-24 AR ARP050104911A patent/AR052034A1/es not_active Application Discontinuation
- 2005-11-25 MY MYPI20055516A patent/MY144320A/en unknown
- 2005-11-25 TW TW094141625A patent/TWI344463B/zh active
- 2005-12-01 PE PE2005001398A patent/PE20061148A1/es not_active Application Discontinuation
- 2005-12-02 WO PCT/US2005/043728 patent/WO2006060712A2/en not_active Ceased
- 2005-12-02 CN CN2005800416393A patent/CN101068793B/zh not_active Expired - Lifetime
- 2005-12-02 ES ES05852840T patent/ES2375788T3/es not_active Expired - Lifetime
- 2005-12-02 US US11/293,678 patent/US7754731B2/en active Active
- 2005-12-02 MX MX2007006639A patent/MX2007006639A/es active IP Right Grant
- 2005-12-02 PT PT05852840T patent/PT1819700E/pt unknown
- 2005-12-02 RS RS20120021A patent/RS52197B/sr unknown
- 2005-12-02 EP EP05852866A patent/EP1819683B1/en not_active Expired - Lifetime
- 2005-12-02 ME MEP-2012-21A patent/ME01985B/me unknown
- 2005-12-02 AU AU2005311671A patent/AU2005311671B8/en not_active Expired
- 2005-12-02 EP EP05852840A patent/EP1819700B1/en not_active Expired - Lifetime
- 2005-12-02 AT AT05852840T patent/ATE534645T1/de active
- 2005-12-02 NZ NZ555376A patent/NZ555376A/en unknown
- 2005-12-02 EA EA200701204A patent/EA012418B1/ru not_active IP Right Cessation
- 2005-12-02 SI SI200531435T patent/SI1819700T1/sl unknown
- 2005-12-02 ES ES05852866T patent/ES2370136T3/es not_active Expired - Lifetime
- 2005-12-02 CA CA2588398A patent/CA2588398C/en not_active Expired - Lifetime
- 2005-12-02 PL PL05852840T patent/PL1819700T3/pl unknown
- 2005-12-02 HR HR20120066T patent/HRP20120066T1/hr unknown
- 2005-12-02 BR BRPI0518760A patent/BRPI0518760A8/pt not_active Application Discontinuation
- 2005-12-02 AT AT05852866T patent/ATE518844T1/de active
- 2005-12-02 KR KR1020077015278A patent/KR101350420B1/ko not_active Expired - Lifetime
- 2005-12-02 JP JP2007544570A patent/JP4705956B2/ja not_active Expired - Lifetime
- 2005-12-02 KR KR1020137028450A patent/KR20130122031A/ko not_active Withdrawn
- 2005-12-02 DK DK05852840.7T patent/DK1819700T3/da active
- 2005-12-02 GE GEAP200510157A patent/GEP20105086B/en unknown
- 2005-12-02 WO PCT/US2005/043781 patent/WO2006060730A2/en not_active Ceased
-
2007
- 2007-05-22 ZA ZA200704130A patent/ZA200704130B/xx unknown
- 2007-05-23 CR CR9146A patent/CR9146A/es not_active Application Discontinuation
- 2007-05-28 NI NI200700138A patent/NI200700138A/es unknown
- 2007-05-31 IL IL183614A patent/IL183614A/en active IP Right Grant
- 2007-06-01 TN TNP2007000215A patent/TNSN07215A1/fr unknown
- 2007-06-29 MA MA30041A patent/MA29120B1/fr unknown
- 2007-07-02 NO NO20073404A patent/NO338784B1/no unknown
-
2010
- 2010-06-04 US US12/793,801 patent/US8357798B2/en active Active
-
2012
- 2012-02-21 CY CY20121100173T patent/CY1112859T1/el unknown
-
2014
- 2014-04-24 AR ARP140101707A patent/AR101429A2/es not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA200704130B (en) | Protassium salt of an HIV integrase inhibitor | |
| EP1756069A4 (en) | HIV INTEGRASE INHIBITORS | |
| IL177189A0 (en) | Hiv integrase inhibitors | |
| IL177858A0 (en) | Hiv integrase inhibitors | |
| TWI366567B (en) | Bicyclic heterocycles as hiv integrase inhibitors | |
| SI1948666T1 (sl) | Hiv integrazni inhibitorji | |
| IL179161A0 (en) | Hiv integrase inhibitors: cyclic pyrimidinone compounds | |
| AU2003248872A8 (en) | Hiv integrase inhibitors | |
| EP1753767A4 (en) | BICYCLIC HETEROCYCLES AS HIV INTEGRASE INHIBITORS | |
| AP2870A (en) | Odcase inhibitors for the treatment of malaria | |
| IL192208A0 (en) | Methods for improving the pharmacokinetics of hiv integrase inhibitors | |
| EP1756092A4 (en) | NEW INHIBITORS OF RHO-KINASEN | |
| EP1749008A4 (en) | BICYCLIC HETEROCYCLES AS HIV INTEGRASE INHIBITORS | |
| AP2005003451A0 (en) | HIV integrase inhibitors. | |
| TWI365876B (en) | Prodrugs of hiv protease inhibitors | |
| EP1910363A4 (en) | INHIBITORS OF HIV INTEGRASE | |
| IL189939A0 (en) | Inhibitors of the hiv integrase enzyme | |
| EP1910356A4 (en) | HIV integrase | |
| EP1910355A4 (en) | HIV integrase | |
| EP1909578A4 (en) | INHIBITORS OF HIV INTEGRASE | |
| ZA200606956B (en) | HIV integrase inhibitors | |
| ZA200806222B (en) | Methods for improving the pharmacokinetics of HIV integrase inhibitors | |
| ZA200609935B (en) | Bicyclic heterocycles as HIV integrase inhibitors | |
| HK1098463A (en) | Hiv integrase inhibitors | |
| ZA200702390B (en) | S-triazolyl α-mercaptoacetanildes as inhibitors of HIV reverse transciptase |